Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
MIC:GEMA's Debt-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.21 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Debt-to-EBITDA Related Terms
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Debt-to-EBITDA Chart
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Debt-to-EBITDA vs Healthcare Providers & Services Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) has a Debt-to-EBITDA of 2.56 as of Dec. 2023. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC.
Is Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Debt-to-EBITDA too high?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's current Debt-to-EBITDA is 2.56. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.21. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's value of 2.56 is 15.8% above this industry median. Overall, Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Debt-to-EBITDA compare to FICO and SPSC?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Debt-to-EBITDA of 2.56 can be compared against companies in the Healthcare Providers & Services industry. The industry median Debt-to-EBITDA is 2.21. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's value of 2.56 is 15.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.21, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's current Debt-to-EBITDA of 2.56 is 15.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's current Debt-to-EBITDA is 2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC stock overvalued right now?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) has a current Debt-to-EBITDA of 2.56. The current Debt-to-EBITDA is 2.56 and 15.8% above the Healthcare Providers & Services industry median of 2.21. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA), the current Debt-to-EBITDA is 2.56 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC, through its subsidiary, is engaged in offering personal storage of cord blood stem cells in Russia and Eastern Europe. The services provided by the company include Cord Blood Cell Preservation, Program for the treatment of Cerebral Palsy, Cord Blood DNA isolation, and Umbilical Cord tissue, among others.
17GF Score
Get the complete analysis for MIC:GEMA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIC:GEMA has been successfully added to your 
